Financial public releases
All Virbac financial public releases

2023 Annual results

2024/03/19 - Financial public releases

●    Revenue up 4.9%, enabling market share gains despite difficulties in 2023

●    2023 operating profitability1 at an all-time high of 23.2% of revenue
     ○ Up 0.4 points compared to 2022 

●    Strong momentum expected in 2024
     ○  Expected revenue growth of 4% to 6% at constant exchange rates and scope
     ○  Operating profitability1 expected to rise by 0,5 point

 

Read more

Virbac to take a leading position in Japan through the acquisition of Sasaeah

2024/03/06 - Financial public releases

Sasaeah.jpgVirbac announces that it has signed a definitive agreement with ORIX Corporation for the acquisition of its animal health subsidiary Sasaeah for an enterprise value of approximately €280 million.

Read more

2023 fourth quarter consolidated sales

2024/01/17 - Financial public releases

Annual revenue growth of +4.9% thanks to record fourth-quarter activity at +11.5%

Read more

Outlook 2023-2024

2023/12/19 - Financial public releases

Read more

Virbac acquired a majority stake in Globion, a leading Indian poultry vaccines specialist

2023/11/02 - Financial public releases

Acquistion_Virbac_octobre_300x200.jpgOn November 1, we successfully finalized the acquisition of a majority stake in Globion. This transaction will bolster our position of animal health leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines. 

Read more

2023 third quarter consolidated sales

2023/10/23 - Financial public releases

Revenue growth at the end of September at +2.8% at constant exchange rates and scope thanks to a strong activity rebound in the third quarter (+7.8% at constant exchange rates and scope).

Read more

Virbac will enter the fast-growing poultry vaccines segment in India

2023/10/09 - Financial public releases

Acquistion_Virbac_octobre_300x200.jpgVirbac announces the signing of an agreement to acquire Globion, a leading Indian poultry vaccines specialist. This transaction will bolster our position of animal health market leader in India by extending Virbac India’s existing poultry portfolio to the growing segment of avian vaccines.

Read more

2023 half year results

2023/09/28 - Financial public releases

Current operating income before R&D slightly improving throughout first half of 2023 in percentage of revenue

Read more

Virbac launches a share buyback program

2023/08/22 - Financial public releases

Following the decision of the board of directors on June 19, 2023 and its approval by the shareholder’s meeting, we are going to buy back 100,000 of our own shares (less than 1.25% of the capital). Main objective: to decrease the company's share capital by canceling treasury shares purchased.

Read more

2023 half-year results: publication postponed to end of September

2023/08/22 - Financial public releases

At the end of August, with our priority systems fully restored and functional following the June cyberattack, we will be able to publish our mid-year results on September 28 with a two-week delay.

Read more

2023 second quarter consolidated sales

2023/07/18 - Financial public releases

Revenue up about 2% during the second quarter and stable at the end of June despite two unfavorable one-off effects throughout the semester

Read more

Virbac reassesses its 2023 growth and Adjusted EBIT1 forecast

2023/07/03 - Financial public releases

Virbac reassesses its 2023 growth and Adjusted EBIT1 forecast

Read more

2023 first quarter consolidated sales

2023/04/17 - Financial public releases

Slight decline in first-quarter revenue primarily due to a base effect as well as a context of market slowdown

Read more

2022 annual results

2023/03/23 - Financial public releases

2022 current operating income on the rise at +8.3%, reflecting the momentum of our business over the year in a slowing market

Read more

2022 fourth quarter consolidated sales

2023/01/18 - Financial public releases

Annual revenue growth of +9.6% at comparable exchange rates and scope (+14.3% at real rates), driven by exceptional business activity in the fourth quarter

Read more

2023 Outlook

2022/12/19 - Financial public releases

Read more

2022 third quarter consolidated sales

2022/10/18 - Financial public releases

Revenue growth at end of September at +7.7% at comparable exchange rates and perimeter (+12.7% at actual rates)

Read more

2022 half year results

2022/09/15 - Financial public releases

Increase in operating income in the first half of 2022 reflecting the dynamism of our business

Read more

2022 second quarter consolidated sales

2022/07/19 - Financial public releases

Growth in revenue in the first half of 2022 of +12.0% at comparable exchange rates (+16.4% at real rates), driven by good performance in all areas

Read more

2022 first quarter consolidated sales

2022/04/14 - Financial public releases

Very strong growth in revenue in the first quarter of 2022 of +16.2% at comparable exchange rates (+19.3% at real rates), driven by good performance in all areas

Read more

2021 Annual results

2022/03/22 - Financial public releases

2021 operating profit from ordinary activities showed very strong growth, reflecting the excellent dynamism of our business in a rapidly growing market

Read more

2021 fourth quarter consolidated sales

2022/01/19 - Financial public releases

Exceptional growth in annual revenue of +18.4% at comparable exchange rates and scope (+14.9% at constant rates and real scope), driven by remarkable performance in a very buoyant market

Read more

United States: Virbac announces the FDA approval of a tulathromycin injectable and a collaboration with Pharmgate

2021/12/08 - Financial public releases

Vignette_300X200_Porc_0000_P1033761.00_00_10_27.Still001.jpgVirbac's first steps into the U.S. food producing animal market.

Read more

Aquaculture : Virbac completes the acquisition of Centrovet

2021/11/05 - Financial public releases

vignette-corpo-centrovet.pngVirbac announces the acquisition of the remaining minority shares of the Centrovet group.

Read more

2021 third quarter consolidated sales

2021/10/18 - Financial public releases

Excellent revenue growth of 21.2% at the end of September at comparable exchange rates and scope (+16.4% at constant rates and real scope), driven by a very solid third-quarter performance again in all areas

Read more

Virbac and Jectas Innovators sign an agreement

2021/09/29 - Financial public releases

partenariat-jectas-vignette-corpo.pngVirbac and Jectas Innovators are proud to announce the signature of a collaborative agreement for the development of animal health vaccine(s).

Read more

2021 half year results

2021/09/15 - Financial public releases

Significant increase in operating profit from ordinary activities for the first half of 2021 due to the sound market performance and dynamism of our business

Read more

Aquaculture : Virbac strengthens its position in Centrovet

2021/09/13 - Financial public releases

vignette-corpo-centrovet.pngVirbac announces the acquisition of additional shares in the Centrovet group.

Read more

2021 second quarter consolidated sales

2021/07/20 - Financial public releases

Exceptional increase in revenue in the first half of 2021, with +21.3% at comparable exchange rates and scope (+14% at constant exchange rates and actual scope), driven by very solid performance in all areas and good market dynamics

Read more

Virbac Corporation in the USA has completed the acquisition of iVet LLC a specialty petfood company

2021/07/08 - Financial public releases

TEVI-Vignette300x200.jpgAs part of its 2030 vision, Virbac completed the acquisition of iVet LLC, a specialty petfood company. This acquisition, in addition to the portfolio of products, will bring us expertise in distribution, logistics and e-commerce which are part of the key to the success of our petfood ambition in the USA.

Read more

Driven by very solid performance in all areas and a very dynamic market, we are raising our outlook for 2021

2021/07/05 - Financial public releases

2021 Outlook

Read more

Virbac completes divestment of the industrial site located in Magny-en-Vexin (Paris) to Friulchem

2021/07/02 - Financial public releases

Magny_2021.jpgVirbac, today announced the successful completion of its divestment of the production plant located in Magny-en-Vexin to FC France SAS, a subsidiary of Friulchem SpA and Finest SpA. 

Read more

Virbac: Rodolphe Durand appointed as non-voting advisor on the board of directors

2021/06/21 - Financial public releases

Durand_Rodolphe-150x200.jpgAs a non-voting advisor, his role will be mainly to support the good governance of our company by strengthening the complementarity of the skills of the board of directors.

Read more

2021 first quarter consolidated sales

2021/04/15 - Financial public releases

Very strong growth in revenue in the first quarter of 2021 at +22.6% at comparable exchange rates and scope (+12.3% at constant rates), driven by very solid performance in all areas
 

Read more

2020 annual results

2021/03/17 - Financial public releases

2020 current operating income showed strong growth (+37.6% at constant rates and scope), reflecting the excellent evolution of revenue (+5.7% at constant rates and scope) and a sharp decrease in expenses in the context of the Covid-19 crisis

Read more

2020 fourth quarter consolidated sales

2021/01/19 - Financial public releases

2020 annual revenue shows strong growth of +5.7% at constant exchange rates and scope (+3.2% at constant rates) 

Read more

2020 third quarter consolidated sales

2020/10/14 - Financial public releases

Revenue grew +6.8% at constant exchange rates and scope at the end of September 2020 (+5.6% at constant rates) thanks to solid third quarter performance

Read more

Virbac governance evolution

2020/10/13 - Financial public releases

Virbac will change its governance at its shareholders' meeting on December 15

Read more

2020 half year results

2020/09/16 - Financial public releases

Operating profit from ordinary activities up sharply for the first half of 2020 reflecting revenue resiliency and strong expenditure restraint during the Covid-19 crisis

Read more

2020 second quarter consolidated sales

2020/07/20 - Financial public releases

Revenue grew by +5.0% at constant exchange rates in the first half of 2020 (+4.5% excluding Sentinel), impacted by a decline in the second quarter of the year

Read more

Divestment of US rights

2020/07/02 - Financial public releases

Virbac completes divestment of U.S. Rights to SENTINEL® brands to MSD Animal Health

Read more

Signing of an agreement

2020/05/13 - Financial public releases

Virbac to divest U.S. Rights to SENTINEL® brands to MSD Animal Health

Read more

2020 first quarter consolidated sales

2020/04/15 - Financial public releases

2020 first quarter revenue rose by +14.3% at comparable exchange rates, significantly impacted by anticipatory buying

Read more

2019 annual results

2020/03/16 - Financial public releases

2019 operating profit from ordinary activities on the rise

Read more

2019 Annual consolidated sales

2020/01/16 - Financial public releases

2019 annual revenue shows strong growth of +6.6% at constant exchange rates

Read more

The Group raises the 2019 annual outlook

2019/12/20 - Financial public releases

Read more

2019 third quarter consolidated sales

2019/10/11 - Financial public releases

Solid +8.4% growth in revenue at constant exchange rates at the end of September, 2019

Read more

Stock exchange: Virbac again in the SBF 120

2019/09/19 - Financial public releases

Following the quarterly review of its indices, the Paris stock exchange operator, Euronext, includes Virbac in the CAC Mid 60 and SBF 120 as from 23 September.

Read more

2019 half year results

2019/09/16 - Financial public releases

Operating profit on the rise in the first half of 2019

Read more

Cyrille Petit appointed as a member of the Virbac supervisory board

2019/07/18 - Financial public releases

Cyrille Petit.jpgVirbac announces the arrival of Cyrille Petit as a member of the supervisory board as of June 18, 2019. In addition, on the audit committee he will replace Olivier Bohuon, who is also a member of the supervisory board.

Read more

2019 second quarter consolidated sales

2019/07/16 - Financial public releases

2019 first half-year revenue grew by +6.6% at constant exchange rates

Read more

2019 first quarter consolidated sales

2019/04/11 - Financial public releases

2019 first quarter revenue rose by +10.9% at comparable exchange rates

Read more

2018 annual results

2019/03/18 - Financial public releases

2018 operating profit from ordinary activities grew by 13.4%

Read more

2018 Annual consolidated sales

2019/01/17 - Financial public releases

2018 annual revenue grew by +4.5% at constant exchange rates

Read more

2018 third quarter consolidated sales

2018/10/11 - Financial public releases

Revenue grew by +5.5% at constant exchange rates at the end of September 2018

Read more

2018 half year results

2018/09/17 - Financial public releases

Operating profit up sharply in the first half of 2018

Read more

2018 second quarter consolidated sales

2018/07/17 - Financial public releases

Revenue grew by +4.3% at constant exchange rates in the second quarter of 2018

Read more

2018 first quarter consolidated sales

2018/04/12 - Financial public releases

2018 first quarter revenue rose by +3.3% at comparable exchange rates

Read more

Webcast 2017 annual results

2018/03/19 - Financial public releases

Read more

2017 annual results

2018/03/14 - Financial public releases

Operating profit from ordinary activities 2017 comparable to 2016

Read more

2017 Annual consolidated sales

2018/01/16 - Financial public releases

Annual sales comparable to 2016 at constant exchange rates after strong fourth-quarter growth

Read more

Aquaculture: Virbac postpones its option to buy Centrovet for three years

2017/11/22 - Financial public releases

By mutual agreement, Virbac and the other shareholders of Centrovet have decided to postpone the option to buy the Chilean aquaculture specialist for three years, under the same pricing conditions.

Read more

2017 third quarter consolidated sales

2017/10/12 - Financial public releases

Virbac: quarterly sales affected by distributor destocking in the United States

Read more

Virbac group: Solène Madelpuech joins the supervisory board

2017/09/22 - Financial public releases

Madelpuech_Solene.jpgOn September 5, 2017, Virbac’s supervisory board co-opted Solène Madelpuech into the supervisory board as a new member. On the same day, Jeanine Dick, aged 81, announced her resignation. 

Read more

2017 half year results

2017/09/11 - Financial public releases

Slight increase in first half results

Read more

2017 second quarter consolidated sales

2017/07/17 - Financial public releases

Virbac: second quarter sales growth largely offsets the decline in the first quarter

Read more

2017 first quarter consolidated sales

2017/04/12 - Financial public releases

First quarter 2017 sales down, strongly impacted by stock effects in the distribution in the United States

Read more

2016 annual results

2017/03/13 - Financial public releases

Strong rebound in profitability in 2016  

Read more

2016 Annual consolidated sales

2017/01/17 - Financial public releases

Annual sales growth of 4.5%, at constant exchange rates

Read more

St. Louis: lifting of the Warning Letter for the Virbac production site

2016/12/16 - Financial public releases

Virbac announces that it has received from the Food and drug administration (FDA) a communication confirming the lifting of the Warning Letter received in December 2015 for its St. Louis production site (Missouri, USA).

Read more

2016 third quarter consolidated sales

2016/10/13 - Financial public releases

Sales grow by 3.2% at the end of September at constant rates

Read more

2016 half year results

2016/09/19 - Financial public releases

Growth of half-year results

Read more

2016 second quarter consolidated sales

2016/07/18 - Financial public releases

Sales growth by 3.6% at constant exchange rates in the first half

Read more

2016 first quarter consolidated sales

2016/04/13 - Financial public releases

Sales in the first quarter 2016 : return to organic growth

Read more

2015 annual results

2016/03/14 - Financial public releases

2015 annual results heavily impacted by the United States

Read more

2015 Annual consolidated sales

2016/01/14 - Financial public releases

Annual sales growth of 10.2%, driven by exchange rates and acquisitions

Read more

2015 third quarter consolidated sales

2015/10/15 - Financial public releases

Virbac : sales grow by 5.5% in the third quarter

Read more

2015 half year results

2015/09/15 - Financial public releases

Half-year results  heavily impacted by the United States

Read more

2015 second quarter consolidated sales

2015/07/16 - Financial public releases

Virbac : sales grow by 18.1% in the first half

Read more

Group's perspectives for 2015 impacted by the industrial situation in the United-States

2015/06/23 - Financial public releases

Group’s perspectives for 2015 impacted by the industrial situation in the United-States

Read more

2015 first quarter consolidated sales

2015/06/15 - Financial public releases

Sales growth of 17.1% in the first quarter

Read more

PEA-PME eligibility of Virbac

2015/03/24 - Financial public releases

Virbac, listed on Euronext Paris

Read more

2014 annual results

2015/03/16 - Financial public releases

Results grow in 2014 following a strong second half

Read more

2014 Annual consolidated sales

2015/01/15 - Financial public releases

Sustained growth in the fourth quarter

Read more

Virbac announces the closing of the SENTINEL® brands family acquisition in the United States

2015/01/05 - Financial public releases

Virbac announces the successful closing on January 2nd of its agreement with Eli Lilly and Company to acquire two major parasiticides for dogs in the United States: SENTINEL® Flavor Tabs® and SENTINEL® SPECTRUM®, marketed up to now by Novartis Animal Health.

Read more

Virbac agrees to acquire veterinary assets from Eli Lilly in the United States

2014/10/27 - Financial public releases

Virbac announces that it has entered into an agreement with Eli Lilly and Company to acquire major United States veterinary products currently marketed by Novartis Animal Health. Eli Lilly has agreed to divest these U.S. assets in connection with the U.S. Federal Trade Commission’s review of Eli Lilly’s pending acquisition of Novartis Animal Health worldwide.

Read more

2014 third quarter consolidated sales

2014/10/16 - Financial public releases

Confirmation of the rebound of growth in the third quarter

Read more

2014 half year results

2014/08/29 - Financial public releases

Half-year results impacted by foreign exchange and the low level of activity in the United States

Read more

2014 second quarter consolidated sales

2014/07/17 - Financial public releases

Organic growth of 3% in the first half

Read more

Annual report 2013 available

2014/04/30 - Financial public releases

The annual report of the fiscal year ending at December 31, 2013 of Virbac is available:
  • download HERE (or in Investors > Financial reports > 2013);
  • or on request, under legal and regulatory conditions.

 

Read more

PEA-PME eligibility of Virbac

2014/04/23 - Financial public releases

Virbac, listed on Euronext Paris

Read more

2014 first quarter consolidated sales

2014/04/15 - Financial public releases

Organic growth of +4.3% in the first quarter

Read more

2013 annual results

2014/03/19 - Financial public releases

Current operating profit increases by 6.9% in 2013

Read more

2013 Annual consolidated sales

2014/01/16 - Financial public releases

Rebound of growth in the last quarter

Read more

2013 third quarter consolidated sales

2013/10/17 - Financial public releases

Slight rebound of organic growth in the third quarter

Read more

2013 half year results

2013/08/30 - Financial public releases

Slight increase of the current operating profit in the first half of 2013

Read more

2013 second quarter consolidated sales

2013/07/18 - Financial public releases

Sales growth of 9.4% in the second quarter

Read more

2013 first quarter consolidated sales

2013/04/16 - Financial public releases

Sales growth of 3.6% in the first quarter

Read more

2012 annual results

2013/03/11 - Financial public releases

A 15.8% net profit increase in 2012

Read more

2012 annual consolidated sales

2013/01/17 - Financial public releases

Sales growth of 11.5% in 2012

Read more

Virbac becomes a leader of the Aquaculture Health Market

2012/11/23 - Financial public releases

VIRBAC announces the signing on November 23d, 2012 of an agreement by which the Group is acquiring a majority stake in CENTROVET, the leader of the animal health market in Chile. This transaction will allow VIRBAC to become a key player in a fast-growing segment of the veterinary market: products used for protection and treatment in aquaculture breeding. 
According to this agreement, VIRBAC has purchased 51% of the shares of the CENTROVET Group from its shareholders and will have the option to acquire the remaining capital stock at the end of a five year period. The transaction is effective as of the date of signing.

Read more

2012 third quarter consolidated sales

2012/10/18 - Financial public releases

Steady growth of sales in the third quarter

Read more

2012 half year results

2012/08/31 - Financial public releases

Strong growth of half-year earnings

Read more

2012 second quarter consolidated sales

2012/07/19 - Financial public releases

Continued solid sales growth in the second quarter

Read more

2012 acquisition

2012/06/25 - Financial public releases

Virbac acquires STOCKGUARD in New-Zealand

Read more

2012 first quarter consolidated sales

2012/04/18 - Financial public releases

Solid sales growth in the first quarter

Read more